GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (OTCPK:OXBDF) » Definitions » ROE % Adjusted to Book Value

OXBDF (Oxford BioMedica) ROE % Adjusted to Book Value : -20.02% (As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Oxford BioMedica ROE % Adjusted to Book Value?

Oxford BioMedica's ROE % for the quarter that ended in Jun. 2024 was -92.89%. Oxford BioMedica's PB Ratio for the quarter that ended in Jun. 2024 was 4.64. Oxford BioMedica's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was -20.02%.


Oxford BioMedica ROE % Adjusted to Book Value Historical Data

The historical data trend for Oxford BioMedica's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica ROE % Adjusted to Book Value Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.29 -0.87 2.19 -9.48 -41.82

Oxford BioMedica Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.51 -6.31 -21.72 -64.15 -20.02

Competitive Comparison of Oxford BioMedica's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oxford BioMedica's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's ROE % Adjusted to Book Value falls into.


';

Oxford BioMedica ROE % Adjusted to Book Value Calculation

Oxford BioMedica's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-116.26% / 2.78
=-41.82%

Oxford BioMedica's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-92.89% / 4.64
=-20.02%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types.